Advertisement

Afatinib

  • Helga Wecker
  • Cornelius F. Waller
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 211)

Abstract

Afatinib (BIBW 2992, US: GilotrifTM, other countries: Giotrif©) is an irreversible blocker of the ErbB family, acting at the tyrosine kinases of these proteins. In 2013, it was approved by the FDA and the EMA for the treatment of adults with advanced, EGFR mutation-positive non-small-cell lung cancer. Further investigations for the treatment of many other tumors with afatinib, e.g., HNSCC and breast cancer, are ongoing.

Keywords

Afatinib EGFR Mutation NSCLC Solid tumors 

References

  1. Afatinib—Compound Summary for CID 10184653. National Center for Biotechnology Information (2017) PubChem Compound Database, CID = 10184653, https://pubchem.ncbi.nlm.nih.gov/compound/10184653. Accessed on 26 Nov 2017
  2. Agus DB, Terlizzi E, Stopfer P, Amelsberg A, Gordon MS (2006) (Hg): a phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours. J Clin Oncol 24(suppl)Google Scholar
  3. Aw DC-W, Tan EH, Chin TM, Lim HL, Lee HY, Soo RA (2017) Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities. Asia-Pac J Clin Oncol.  https://doi.org/10.1111/ajco.12687
  4. Bahleda R, Hollebecque A, Varga A, Gazzah A, Massard C, Deutsch E et al (2015) Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. Br J Cancer 113(10):1413–1420.  https://doi.org/10.1038/bjc.2015.374CrossRefPubMedPubMedCentralGoogle Scholar
  5. Barron F, de la Torre-Vallejo M, Luna-Palencia RL, Cardona AF, Arrieta O (2016) The safety of afatinib for the treatment of non-small cell lung cancer. Expert Opin Drug Saf 15(11):S.1563–1572.  https://doi.org/10.1080/14740338.2016.1236910
  6. Burtness B, Bourhis JP, Vermorken JB, Harrington KJ, Cohen EEW (2014) Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials 15:S.469.  https://doi.org/10.1186/1745-6215-15-469
  7. Chu QS, Sangha R, Hotte SJ, Sergenson G, Schnell D, Chand VK, Hirte HW (2014) A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. Invest New Drugs 32(6):1226–1235.  https://doi.org/10.1007/s10637-014-0139-9CrossRefPubMedGoogle Scholar
  8. Cohen S (1983) The epidermal growth factor (EGF). Cancer 51(10):1787–1791CrossRefPubMedGoogle Scholar
  9. Cohen EEW, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM et al (2017) Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Ann Oncol 28(10):2526–2532.  https://doi.org/10.1093/annonc/mdx344CrossRefPubMedGoogle Scholar
  10. Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S et al (2015) Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncol 16(16):1700–1710.  https://doi.org/10.1016/S1470-2045(15)00373-3CrossRefPubMedGoogle Scholar
  11. Dunn LA, Fury MG, Sherman EJ, Ho AA, Katabi N, Haque SS, Pfister DG (2017) Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer. Head Neck 101:S.292.  https://doi.org/10.1002/hed.24938
  12. Eberl M, Klingler S, Mangelberger D, Loipetzberger A, Damhofer H, Zoidl K et al (2012) Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. EMBO Mol Med 4(3):218–233.  https://doi.org/10.1002/emmm.201100201CrossRefPubMedPubMedCentralGoogle Scholar
  13. Fan Z, Baselga J, Masui H, Mendelsohn J (1993) Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53(19):4637–4642PubMedGoogle Scholar
  14. Gazzah A, Boni V, Soria J-C, Holgado E, Even C, Ould Kaci M et al (2015) Phase Ib study of afatinib plus standard-dose cetuximab in patients (pts) with advanced solid tumors. JCO 33(15_suppl):S.2536.  https://doi.org/10.1200/jco.2015.33.15_suppl.2536
  15. Geater SL, Xu C-R, Zhou C, Hu C-P, Feng J, Lu S et al (2015) Symptom and quality of life improvement in LUX-Lung 6: an open-label phase III study of afatinib versus cisplatin/gemcitabine in Asian patients with EGFR mutation-positive advanced non–small-cell lung cancer. J Thorac Oncol 10(6):883–889.  https://doi.org/10.1097/JTO.0000000000000517CrossRefPubMedGoogle Scholar
  16. Harbeck N, Huang C-S, Hurvitz S, Yeh D-C, Shao Z, Im S-A et al (2016) Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol 17(3):357–366.  https://doi.org/10.1016/S1470-2045(15)00540-9CrossRefPubMedGoogle Scholar
  17. Hirsh V (2015) Next-generation covalent irreversible kinase inhibitors in NSCLC: focus on afatinib. BioDrugs 29(3):167–183.  https://doi.org/10.1007/s40259-015-0130-9
  18. Hochmair M, Holzer S, Burghuber OC (2016) Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases. Anticancer Drugs 27(9):914–915.  https://doi.org/10.1097/CAD.0000000000000410CrossRefPubMedGoogle Scholar
  19. Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M et al (2015) Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)–pretreated non–small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol 10(1):156–163.  https://doi.org/10.1097/JTO.0000000000000380CrossRefPubMedGoogle Scholar
  20. Ioannou N, Dalgleish AG, Seddon AM, Mackintosh D, Guertler U, Solca F, Modjtahedi H (2011) Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br J Cancer 105(10):1554–1562.  https://doi.org/10.1038/bjc.2011.396CrossRefPubMedPubMedCentralGoogle Scholar
  21. Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama EM et al (2013) Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J Nucl Med: Off Publ Soc Nucl Med 54(6):936–943.  https://doi.org/10.2967/jnumed.112.110239CrossRefGoogle Scholar
  22. Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A et al (2013) LUX-Lung 4: a phase II trial of afatinib in patients with advanced non–small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. JCO 31(27):3335–3341.  https://doi.org/10.1200/JCO.2012.45.0981CrossRefGoogle Scholar
  23. Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141(7):1117–1134.  https://doi.org/10.1016/j.cell.2010.06.011CrossRefPubMedPubMedCentralGoogle Scholar
  24. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR et al (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34):4702–4711.  https://doi.org/10.1038/onc.2008.109CrossRefPubMedPubMedCentralGoogle Scholar
  25. Li S-H, Liu C-Y, Hsu P-C, Fang Y-F, Wang C-C, Kao K-C et al (2017) Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases. Expert Rev Anticancer Ther 18(1):81–89.  https://doi.org/10.1080/14737140.2018.1409623CrossRefPubMedGoogle Scholar
  26. Lohinai Z, Hoda MA, Fabian K, Ostoros G, Raso E, Barbai T et al (2015) Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma. J Thorac Oncol 10(5):S.738–746.  https://doi.org/10.1097/jto.0000000000000492
  27. Machiels J-PH, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB et al (2015) Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 16(5):583–594.  https://doi.org/10.1016/S1470-2045(15)70124-5CrossRefPubMedGoogle Scholar
  28. Mao X, Chen Z, Zhao Y, Yu Y, Guan S, Woodfield SE et al (2017) Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma. Oncotarget 8(1):1555–1568.  https://doi.org/10.18632/oncotarget.13657CrossRefPubMedGoogle Scholar
  29. Miller VA, Hirsh V, Cadranel J, Chen Y-M, Park K, Kim S-W et al (2012) Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 13(5):528–538.  https://doi.org/10.1016/S1470-2045(12)70087-6CrossRefPubMedGoogle Scholar
  30. Minkovsky N, Berezov A (2008) BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs (London, Engl: 2000) 9(12):S.1336–1346Google Scholar
  31. Modjtahedi H, Dean C (1994) The receptor for EGF and its ligands—expression, prognostic value and target for therapy in cancer (review). Int J Oncol 4(2):277–296PubMedGoogle Scholar
  32. Modjtahedi H, Cho BC, Michel MC, Solca F (2014) A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn-Schmiedeberg’s Arch Pharmacol 387(6):S.505–521.  https://doi.org/10.1007/s00210-014-0967-3
  33. Molife LR, Omlin A, Jones RJ, Karavasilis V, Bloomfield D, Lumsden G et al (2014) Randomized phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncol 10(2):S.219–231.  https://doi.org/10.2217/fon.13.250
  34. Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N et al (2017) A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. Lung Cancer (Amsterdam, Neth) 108:S.154–160.  https://doi.org/10.1016/j.lungcan.2017.03.009
  35. Mukai H, Masuda N, Ishiguro H, Mitsuma A, Shibata T, Yamamura J et al (2015) Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. Cancer Chemother Pharmacol 76(4):739–750.  https://doi.org/10.1007/s00280-015-2826-4CrossRefPubMedGoogle Scholar
  36. Ninomiya T, Takigawa N, Ichihara E, Ochi N, Murakami T, Honda Y et al (2013) afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther 12(5):589–597.  https://doi.org/10.1158/1535-7163.MCT-12-0885CrossRefPubMedGoogle Scholar
  37. Park K, Tan E-H, O’Byrne K, Zhang L, Boyer M, Mok T et al (2016) Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 17(5):577–589.  https://doi.org/10.1016/S1470-2045(16)30033-XCrossRefPubMedGoogle Scholar
  38. Paz-Ares L, Tan E-H, O’Byrne K, Zhang L, Hirsh V, Boyer M et al (2017) Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 28(2):270–277.  https://doi.org/10.1093/annonc/mdw611CrossRefPubMedPubMedCentralGoogle Scholar
  39. Poindessous V, Ouaret D, El Ouadrani K, Battistella A, Megalophonos VF, Kamsu-Kom N et al (2011) EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin Cancer Res 17(20):6522–6530.  https://doi.org/10.1158/1078-0432.CCR-11-1607CrossRefPubMedGoogle Scholar
  40. Quesnelle KM, Grandis JR (2011) Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res 17(18):5935–5944.  https://doi.org/10.1158/1078-0432.CCR-11-0370CrossRefPubMedPubMedCentralGoogle Scholar
  41. Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P et al (2014) Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro-Oncology.  https://doi.org/10.1093/neuonc/nou160
  42. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A et al (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest  https://doi.org/10.1172/jci38746
  43. Ring A, Wheatley D, Hatcher H, Laing R, Plummer R, Uttenreuther-Fischer M et al (2015) Phase I study to assess the combination of afatinib with trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 21(12):2737–2744.  https://doi.org/10.1158/1078-0432.CCR-14-1812CrossRefGoogle Scholar
  44. Roskoski R (2014) The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 79:34–74.  https://doi.org/10.1016/j.phrs.2013.11.002CrossRefPubMedGoogle Scholar
  45. Schuler M, Yang JC-H, Park K, Kim J-H, Bennouna J, Chen Y-M et al (2016) Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann Oncol 27(3):417–423.  https://doi.org/10.1093/annonc/mdv597CrossRefPubMedGoogle Scholar
  46. Schütze C, Dörfler A, Eicheler W, Zips D, Hering S, Solca F et al (2007) Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol 183(5):256–264.  https://doi.org/10.1007/s00066-007-1696-zCrossRefPubMedGoogle Scholar
  47. Sequist LV, Yang JC-H, Yamamoto N, O’Byrne K, Hirsh V, Mok T et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol: Off J Am Soc Clin Oncol 31(27):S.3327–3334.  https://doi.org/10.1200/jco.2012.44.2806
  48. Sigismund S, Avanzato D, Lanzetti L (2017) Emerging functions of the EGFR in cancer. Mol Oncol.  https://doi.org/10.1002/1878-0261.12155
  49. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C et al (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343(2):342–350.  https://doi.org/10.1124/jpet.112.197756CrossRefPubMedGoogle Scholar
  50. Soria J-C, Felip E, Cobo M, Lu S, Syrigos K, Lee KH et al (2015) Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 16(8):897–907.  https://doi.org/10.1016/S1470-2045(15)00006-6CrossRefPubMedGoogle Scholar
  51. Suder A, Ang JE, Kyle F, Harris D, Rudman S, Kristeleit R et al (2015) A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. Eur J Cancer 51(16):2275–2284.  https://doi.org/10.1016/j.ejca.2015.07.041CrossRefPubMedGoogle Scholar
  52. Vermorken JB, Rottey S, Ehrnrooth E, Pelling K, Lahogue A, Wind S, Machiels J-P (2013) A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. Ann Oncol: Off J Eur Soc Med Oncol 24(5):1392–1400.  https://doi.org/10.1093/annonc/mds633CrossRefGoogle Scholar
  53. Wang S-Q, Liu S-T, Zhao B-X, Yang F-H, Wang Y-T, Liang Q-Y et al (2015) Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1. Oncotarget 6(28):26142–26160.  https://doi.org/10.18632/oncotarget.4536CrossRefPubMedPubMedCentralGoogle Scholar
  54. Wind S, Schnell D, Ebner T, Freiwald M, Stopfer P (2017) Clinical pharmacokinetics and pharmacodynamics of afatinib. Clin Pharmacokinet 56(3):235–250.  https://doi.org/10.1007/s40262-016-0440-1CrossRefPubMedGoogle Scholar
  55. Wong CH, Ma BBY, Hui CWC, Tao Q, Chan ATC (2015) Preclinical evaluation of afatinib (BIBW2992) in esophageal squamous cell carcinoma (ESCC). Am J Cancer Res 5(12):S.3588–3599Google Scholar
  56. Wu Y-L, Zhou C, Hu C-P, Feng J, Lu S, Huang Y et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15(2):213–222.  https://doi.org/10.1016/S1470-2045(13)70604-1CrossRefPubMedGoogle Scholar
  57. Xue C, Tian Y, Zhang J, Zhao Y, Zhan J, Fang W, Zhang L (2016) In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma. Drug Des Dev Ther 10:1299–1306.  https://doi.org/10.2147/DDDT.S94432CrossRefGoogle Scholar
  58. Yang JC-H, Shih J-Y, Su W-C, Hsia T-C, Tsai C-M, Ou S-HI et al (2012) Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 13(5):S.539–548.  https://doi.org/10.1016/s1470-2045(12)70086-4
  59. Yang JC-H, Hirsh V, Schuler M, Yamamoto N, O’Byrne KJ, Mok TSK et al (2013) Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. JCO 31(27):S.3342–3350.  https://doi.org/10.1200/jco.2012.46.1764
  60. Yang JC-H, Sequist LV, Geater SL, Tsai C-M, Mok TSK, Schuler M et al (2015) Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 16(7):S.830–838.  https://doi.org/10.1016/s1470-2045(15)00026-1
  61. Yang JC-H, Wu Y-L, Schuler M, Sebastian M, Popat S, Yamamoto N et al (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16(2):S.141–151.  https://doi.org/10.1016/s1470-2045(14)71173-8
  62. Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J (2017) Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: a meta-analysis. Int J Cancer 140(12):2805–2819.  https://doi.org/10.1002/ijc.30691CrossRefPubMedGoogle Scholar
  63. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H et al (2010) Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. JCO 28(25):3965–3972.  https://doi.org/10.1200/JCO.2009.26.7278CrossRefGoogle Scholar
  64. Young NR, Soneru C, Liu J, Grushko TA, Hardeman A, Olopade OI et al (2015) Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Target Oncol 10(4):501–508.  https://doi.org/10.1007/s11523-014-0353-6CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre Freiburg, and Faculty of MedicineUniversity of FreiburgFreiburgGermany

Personalised recommendations